BioVentrix said it successfully implanted its micro-anchor Revivent device into a 64-year-old female patient suffering from heart failure symptoms following a heart attack.
The first-in-human test follows a similar successful procedure in a pre-clinical model last December. Researchers used Revivent in what it refers to as LIVE (less-invasive ventricular enhancement) a transcatheter-based procedure designed to reshape and reduce the size of the wall of the heart’s left ventricle.
Revivent is designed to eliminate the need for cardiopulmonary bypass or incisions in the heart. Instead, the transcatheter procedure enables placement of small titanium anchors along the heart’s outer surface and along one of the inside walls, according to BioVentrix. The anchors are then pulled toward each another in a way that excludes scarred and non-functioning portions of the heart wall.
BioVentrix’s test patient underwent the procedure at Vilnius University Hospital in Lithuania.
Lon Annest, BioVentrix’s chief medical officer, said that the 1st-in-human test of Revivent was a major step for his company’s development.
“This is a significant step for not only the company, but for all heart failure patients who suffer from ischemic cardiomyopathy,” Annest said in prepared remarks.
The company, which is based in San Ramon, Calif., and Vilnius, raised $14 million last December in a new round of equity funding involving 64 anonymous investors.